{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:19:49Z","timestamp":1776867589970,"version":"3.51.2"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10557-020-07093-8","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T07:02:41Z","timestamp":1602831761000},"page":"871-873","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Aspirin for Primary Cardiovascular Prevention in Patients with Family History of Cardiovascular Disease: Meta-analysis"],"prefix":"10.1007","volume":"35","author":[{"given":"Miguel M.","family":"Antunes","sequence":"first","affiliation":[]},{"given":"Mariana","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Fausto J.","family":"Pinto","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-5673","authenticated-orcid":false,"given":"Daniel","family":"Caldeira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"issue":"9678","key":"7093_CR1","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"C Baigent","year":"2009","unstructured":"Baigent C, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849\u201360.","journal-title":"Lancet"},{"key":"7093_CR2","doi-asserted-by":"crossref","unstructured":"Caldeira D, et al. Aspirin in the primary prevention of cardiovascular disease on diabetic patients: systematic review and meta-analysis. Prim Care Diabetes. 2019.","DOI":"10.1016\/j.pcd.2019.11.004"},{"issue":"11","key":"7093_CR3","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596\u2013646.","journal-title":"Circulation"},{"issue":"23","key":"7093_CR4","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1001\/jama.2014.15690","volume":"312","author":"Y Ikeda","year":"2014","unstructured":"Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. Jama. 2014;312(23):2510\u201320.","journal-title":"Jama"},{"issue":"13","key":"7093_CR5","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa050613","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JAE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293\u2013304.","journal-title":"N Engl J Med"},{"key":"7093_CR6","doi-asserted-by":"crossref","unstructured":"Final report on the aspirin component of the ongoing Physicians\u2019 Health Study. N Engl J Med. 1989;321(3):129\u201335.","DOI":"10.1056\/NEJM198907203210301"},{"issue":"4","key":"7093_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1089\/jwh.2011.2990","volume":"21","author":"CM Rivera","year":"2012","unstructured":"Rivera CM, Song J, Copeland L, Buirge C, Ory M, McNeal CJ. Underuse of aspirin for primary and secondary prevention of cardiovascular disease events in women. J Women\u2019s Health (Larchmt). 2012;21(4):379\u201387.","journal-title":"J Women\u2019s Health (Larchmt)"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07093-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-020-07093-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07093-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T15:43:04Z","timestamp":1669218184000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-020-07093-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["7093"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-07093-8","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,16]]},"assertion":[{"value":"8 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: DC\u00a0has participated in educational meetings and\/or attended a conferences or symposia (including travel, accommodation) with Daiichi Sankyo, Menarini, Merck Serono and Roche, in the last 3 years . MA has participated in conferences with Boehringer-Ingelheim, AstraZeneca, Bayer, Bristol-Myers-Squibb- Gr\u00fcnenthal, Tecnimede, and Merk Sharp & Dohme. FJP had consultant and speaker fees with AstraZeneca, Bayer, BMS, Boehringer Ingelheim, and Daiichi Sankyo. JJF had speaker and consultant fees with Grunenthal, Funda\u00e7\u00e3o MSD (Portugal), TEVA, MSD, Allergan, Medtronic, GlaxoSmithKline, Novartis, Lundbeck, Solvay, BIAL, Merck-Serono, Merz, Ipsen, Biogen, Acadia, Allergan, Abbvie, Sunovion-Pharmaceuticals. MMA has nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The ethical approval and patient informed consent were not required because no patient-level data is involved for this systematic review and meta-analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}